文献速递淋巴瘤

同步抗病毒-免疫化疗策略安全克服弥漫大B细胞淋巴瘤高乙肝病毒载量障碍:多中心队列研究

Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.
PubMed 文献 · Br J Haematol · 2026-06-02

该多中心回顾性研究分析1120例新诊断DLBCL中112例慢性HBV感染者,按基线病毒载量分层(低载量<10^4 IU/mL 82例,高载量≥10^4 IU/mL 30例),评估抗病毒时机、病毒学动态及临床结局。结果显示同步启动抗病毒预防(主要为恩替卡韦)可安全有效抑制高载量患者HBV DNA,3年累积HBV再激活率低(总体4.2%),高、低载量组疗效相当。

要点

  • 同步启动抗病毒预防与免疫化疗可安全有效预防高HBV DNA DLBCL患者HBV再激活。
  • 高载量组与低载量组3年无进展生存、总缓解率及完全缓解率无显著差异。
  • 抗病毒药物(主要为恩替卡韦)可将高载量患者HBV DNA抑制至检测不到水平。

核心结论

  • 同步启动抗病毒预防与免疫化疗安全有效,可预防高HBV DNA载量DLBCL患者HBV再激活,并使免疫化疗及时进行。

研究设计与样本

  • 多中心回顾性研究,分析1120例新诊断DLBCL患者中112例慢性HBV感染者,按基线病毒载量分层(低载量<10^4 IU/mL 82例,高载量≥10^4 IU/mL 30例)。

主要发现

  • 抗病毒药物(主要为恩替卡韦)将高载量患者HBV DNA抑制至检测不到水平(中位起始1.65×10^6 IU/mL,p=0.001)。
  • 3年累积HBV再激活率低(总体4.2%;高载量4.5% vs 低载量4.1%,p=0.955),发生1例停药后致命性HBV再激活。
  • 肝毒性轻微(1-2级转氨酶升高33.3%-36.7%)。
  • 高、低载量组3年无进展生存率(80.9% vs 70.6%,p=0.137)、总缓解率(86.7% vs 82.9%)及完全缓解率(70.0% vs 64.6%)相当。
  • 倾向性评分匹配分析证实无进展生存或HBV再激活无显著差异。

关键数值与推荐

  • 高病毒载量定义为基线HBV DNA≥4 log10 IU/mL(即≥10^4 IU/mL)。
  • 低病毒载量定义为基线HBV DNA<10^4 IU/mL。

临床怎么用

  • 对高HBV DNA载量DLBCL患者,可同步启动抗病毒预防(如恩替卡韦)与免疫化疗,无需延迟免疫化疗。
  • 治疗期间需监测HBV DNA及肝功能,停药后仍需警惕HBV再激活风险。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 高病毒载量组样本量较小(30例)。
  • 抗病毒药物以恩替卡韦为主,其他药物数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although antiviral prophylaxis is standard for lymphoma patients with chronic hepatitis B virus (HBV) infection to prevent HBV reactivation (HBVr), the optimal timing for high-risk patients (baseline HBV deoxyribonucleic acid (DNA) ≥4 log10 IU/mL) during immunochemotherapy remains unclear. A multicentre retrospective study analysed 112 chronic HBV patients among 1120 newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, stratified by baseline viral load (low: <104 IU/mL, n = 82; high: ≥104 IU/mL, n = 30). We assessed antiviral timing, virological dynamics and clinical outcomes. Antivirals (mainly entecavir) suppressed HBV DNA to undetectable levels in high-load patients (median start 1.65 × 106 IU/mL; p = 0.001). The 3-year cumulative HBVr rates were low (4.2% overall; 4.5% high vs. 4.1% low load, p = 0.955), with one fatal HBVr after discontinuation. Liver toxicity was mild (grade 1-2 transaminase elevations: 33.3%-36.7%). High and low viral load groups achieved comparable 3-year progression-free survival (80.9% vs. 70.6%, p = 0.137), overall response rates (86.7% vs. 82.9%) and complete remission rates (70.0% vs. 64.6%). Propensity score-matched analysis confirmed no significant differences in progression-free survival or HBVr. Concurrent initiation of antiviral prophylaxis with immunochemotherapy is safe and effective, preventing HBVr and enabling timely immunochemotherapy in DLBCL patients with high HBV DNA levels.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Guo J, Wang X, et al. Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study. Br J Haematol. 2026. PMID: 42226728. doi:10.1111/bjh.70584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。